Rapt Therapeutics (NASDAQ:RAPT – Get Free Report) and 180 Life Sciences (NASDAQ:ATNF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and target prices for Rapt Therapeutics and 180 Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapt Therapeutics | 1 | 5 | 4 | 2 | 2.58 |
| 180 Life Sciences | 1 | 0 | 0 | 0 | 1.00 |
Rapt Therapeutics presently has a consensus price target of $24.78, indicating a potential downside of 15.55%. Given Rapt Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Rapt Therapeutics is more favorable than 180 Life Sciences.
Risk & Volatility
Institutional & Insider Ownership
99.1% of Rapt Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 2.4% of Rapt Therapeutics shares are owned by insiders. Comparatively, 38.2% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Rapt Therapeutics and 180 Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapt Therapeutics | N/A | -67.92% | -59.59% |
| 180 Life Sciences | N/A | -141.25% | -80.77% |
Valuation and Earnings
This table compares Rapt Therapeutics and 180 Life Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapt Therapeutics | $1.53 million | 317.18 | -$129.87 million | ($14.17) | -2.07 |
| 180 Life Sciences | N/A | N/A | -$6.17 million | ($15.07) | -0.11 |
180 Life Sciences has lower revenue, but higher earnings than Rapt Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Rapt Therapeutics beats 180 Life Sciences on 9 of the 13 factors compared between the two stocks.
About Rapt Therapeutics
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
About 180 Life Sciences
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Receive News & Ratings for Rapt Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapt Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
